Gamal et al., 2014 - Google Patents
Tracing the antibody mediated acquired immunity by Foot and Mouth disease and Rift Valley Fever combined vaccine in pregnant ewes and their lambs.Gamal et al., 2014
View PDF- Document ID
- 7355650249021204342
- Author
- Gamal W
- Soliman E
- El-Manzalawy M
- Publication year
- Publication venue
- Veterinary World
External Links
Snippet
Aim: The aim of this study is to provide adequate protection to ewes and their lambs against Foot and Mouth disease (FMD) and Rift Valley Fever (RVF). Materials and Methods: A combined inactivated FMD and RVF oil vaccine was prepared successfully. Such vaccine …
- 208000000705 Rift Valley Fever 0 title abstract description 80
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lubroth et al. | Identification of native foot-and-mouth disease virus non-structural protein 2C as a serological indicator to differentiate infected from vaccinated livestock | |
| Kim et al. | Development of inactivated trivalent vaccine for the teratogenic Aino, Akabane and Chuzan viruses | |
| FROST et al. | Vaccination of Atlantic salmon with recombinant VP2 of infectious pancreatic necrosis virus (IPNV), added to a multivalent vaccine, suppresses viral replication following IPNV challenge | |
| RU2595873C2 (en) | Bovine viral diarrhoea virus type 1b vaccine compositions and methods for production and use thereof | |
| Diaz-San Segundo et al. | Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine | |
| WO2008148149A1 (en) | Method of treatment or inhibition of enterovirus 71 infection | |
| El-Sayed et al. | Studies on the duration of immunity induced in cattle after natural FMD infection and post vaccination with bivalent oil vaccine | |
| US7309493B2 (en) | Inactivated bovine scours vaccines, process and method of preventing bovine scours | |
| Callis et al. | Foot-and-mouth disease | |
| Gamal et al. | Tracing the antibody mediated acquired immunity by Foot and Mouth disease and Rift Valley Fever combined vaccine in pregnant ewes and their lambs. | |
| RU2699671C1 (en) | Vaccine for early protection against foot-and-mouth disease of type o inactivated emulsion | |
| Elhelw et al. | Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels | |
| Tulu Robi et al. | Managing viral challenges in dairy calves: strategies for controlling viral infections | |
| RU2665849C1 (en) | Inactivated emulsion vaccine against foot-and-mouth disease type o | |
| CN102380095A (en) | FMD trivalence polypeptide vaccine and preparation method and application thereof | |
| Erickson et al. | Comparative efficacy of modified-live and inactivated vaccines in boosting disease-sparing responses to bovine viral diarrhea virus challenge in neonatally mucosally primed weanling beef calves | |
| JP7672162B2 (en) | Method for preparing a serum composition for preventing or treating mucous membrane-associated infectious diseases in young mammals, serum composition prepared by said method and use thereof | |
| KR102151962B1 (en) | Method for producing serum composition for preventing or treating infectious disease in young mammal, serum composition produced by the same method, and uses thereof | |
| Araghi et al. | Evaluation of Immunogenicity of Clostridium perfringens Type B Toxoid and Inactivated FMD (O) Virus with Adjuvant (ISA70-MF59) | |
| Jannat et al. | Seroprevalance and molecular detection of FMDV in cattle at Savar in Bangladesh | |
| Gough et al. | A viral subunit immunogen for porcine transmissible gastroenteritis | |
| RU2804875C1 (en) | Culture inactivated adsorbed vaccine against fmd of sat-2/vii genotype from sat-2/eritrea/1998 strain | |
| RU2835906C1 (en) | Inactivated cultural sorbed vaccine against foot-and-mouth disease of genotype sat-2/xiv from strain "sat-2/xiv/2023" | |
| RU2603255C1 (en) | STRAIN A N2155/Baikal/2013 OF MURRAIN VIRUS Aphtae epizooticae TYPE A FOR CONTROL OF ANTIGENIC AND IMMUNOGENIC ACTIVITY AND TO PRODUCE BIOPREPARATIONS FOR DIAGNOSTICS AND SPECIFIC PREVENTION OF MURRAIN TYPE A | |
| RU2824662C1 (en) | Culture inactivated emulsion vaccine against foot-and-mouth disease of asia-1/g-v genotype from asia-1/g-v/2006 strain |